Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Efficacy of Balloon Tamponade in Post-partum Hemorrhage Within 24 Hours After Delivery (BT-PPH)

22 september 2026 uppdaterad av: maryam aslam, Aziz Fatimah Medical & Dental College, Faisalabad

Postpartum hemorrhage (PPH) is a major cause of maternal death, especially in developing countries like Pakistan where it accounts for up to 34% of maternal deaths. When bleeding after delivery does not stop with medicines like oxytocin and uterine massage, a low-cost method called balloon tamponade can be life-saving.

This study titled "Efficacy of Balloon Tamponade in Post-partum Hemorrhage within 24 Hours After Delivery" will be conducted by Dr. Maryam Aslam (PGR Gynecology and Obstetrics) under supervision of Prof. Dr. Raheela Farhat at Aziz Fatima Hospital, Faisalabad.

The objective is to determine the efficacy of intrauterine balloon tamponade (condom catheter balloon) in controlling primary PPH. Efficacy is defined as successful control of bleeding within six hours of balloon insertion without need for additional surgery, confirmed by absence of active vaginal bleeding, a contracted uterine fundus, and stable maternal condition after removal of the balloon. The results will help promote a simple, effective procedure that can even be used by primary health care workers to reduce maternal mortality.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Detaljerad beskrivning

This is a Descriptive Cross-Sectional Study.

Title: Efficacy of Balloon Tamponade in Post-partum Hemorrhage within 24 hours after delivery.

Setting: Department of Obstetrics and Gynecology, Aziz Fatima Hospital, Faisalabad.

Duration: Six months after approval from CPSP. Sample Size: 121 patients, calculated by WHO sample size calculator using anticipated proportion 81%, significance level 5%, margin of error 7%.

Sampling Technique: Consecutive non-probability sampling.

Operational Definitions:

  1. Postpartum Haemorrhage (PPH): Blood loss of more than 500 ml (one kidney tray) following vaginal delivery and 1000 ml following cesarean section within 24 hours. Estimation by kidney tray method.
  2. Efficacy: Successful control of PPH within six hours of balloon insertion, without need for additional surgical intervention. Success is confirmed by absence of active vaginal bleeding, contracted uterine fundus, and stable maternal condition following gradual deflation and removal of the balloon device.

Inclusion Criteria:

  • Age 18-35 years
  • Gestational age between 31 to 41 weeks
  • Having primary PPH

Exclusion Criteria:

  • Obstetric hemorrhage (Antepartum Hemorrhage) <31 weeks of gestation
  • Multiparity (Children more than 5)
  • Traumatic PPH (cervical and vaginal tears)
  • Allergy to latex
  • Acute uterine infection (chorioamnionitis)
  • Cases with bleeding disorders, ruptured uterus
  • Patient whose PPH is managed successfully with uterine curettage

Data Collection Procedure:

After approval from Institutional Ethical Committee (Ref: IEC/392-25 dated 30/09/2025) and CPSP, and informed consent from patients. Patients meeting inclusion criteria will be selected. A proforma will be used to document demographic data. Women with PPH who do not improve with uterotonics will be evaluated for treatment with condom and Foley catheter balloon. A condom-lined sterile rubber catheter will be inserted into the uterus under strict aseptic technique. The balloon will be placed on cervix and held with roller gauze and sponge-holding forceps. 300-400 ml of regular normal saline will be used to inflate the condom. The catheter condom will be stored for up to six hours. If no active bleeding is detected through the cervix and uterine fundus is felt contracted after 6 hours, balloon will be slowly deflated at rate of 50 ml/hour to half its volume in 2 hours. If no further bleeding occurs during next 30 minutes, balloon will be removed in presence of senior staff member. If bleeding persists or uterine fundus rises, condom tamponade will be abandoned and surgical intervention will be pursued.

Data Analysis:

Data will be entered into SPSS version 25. Mean and standard deviation will be calculated for quantitative variables such as age, gestational age, blood loss. Frequencies and percentages will be used for categorical variables such as socioeconomic status, education status, booking status, parity, mode of delivery and efficacy. Chi-square test will be applied to efficacy. Effect modifiers like age, gestational age, blood loss, socioeconomic status, education status, booking status, parity, mode of delivery will be controlled by stratification. Post-stratification chi-square test will be applied and P-value <0.05 will be considered statistically significant.

Studietyp

Observationell

Inskrivning (Beräknad)

121

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Punjab Province
      • Faisalābad, Punjab Province, Pakistan, 38000

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 35 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Women aged 18-35 years with gestational age 31-41 weeks presenting with primary postpartum hemorrhage unresponsive to medical management at Department of Obstetrics and Gynaecology, Allied Hospital Faisalabad. Total 121 participants selected via consecutive non-probability sampling as per WHO sample size calculator with 7% margin of error.

Beskrivning

Inclusion Criteria:

  • Age 18-35 years
  • Having gestational age between 31 to 41 weeks
  • Having PPH (Primary postpartum hemorrhage unresponsive to uterotonics)

Exclusion Criteria:

  • Patient who has Obstetric hemorrhage (Antepartum Hemorrhage) <31 weeks of gestation
  • Multiparity (Children more than 5)
  • Traumatic PPH (cervical and vaginal tears)
  • Allergy to latex
  • Acute uterine infection (chorioamnionitis)
  • Cases with bleeding disorders, ruptured uterus
  • Patient whose postpartum hemorrhage is managed successfully with uterine curettage

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: OTHER
  • Tidsperspektiv: CROSS_SECTIONAL

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
This cohort includes 121 women aged 18-35 years with gestational age 31-41 weeks who developed prima

A condom-lined sterile rubber catheter will be inserted into the uterus under strict aseptic conditions. Balloon placed on cervix and held with roller gauze and sponge-holding forceps. Balloon inflated with 300-400 ml of regular normal saline and kept for up to six hours. If no active bleeding detected through cervix and uterine fundus felt contracted after 6 hours, balloon will be slowly deflated at rate of 50 ml/hour to half its volume in 2 hours. If no further bleeding during next 30 minutes, balloon removed in presence of senior staff. If bleeding persists or fundus rises, tamponade abandoned and surgical intervention pursued. Efficacy defined as successful control of PPH within six hours of insertion without need for additional surgery, confirmed by absence of active vaginal bleeding, contracted uterine fundus and stable maternal condition.

Condom-lined sterile rubber catheter inserted into uterus under aseptic technique, held with roller gauze and sponge-holding forceps. Balloon inflated with 300-400 ml normal saline and kept up to 6 hours. If no active bleeding and uterine fundus contracted after 6 hours, balloon deflated at 50 ml/hour to half volume in 2 hours then removed if no bleeding in next 30 min in presence of senior staff. If bleeding persists, tamponade abandoned and surgical intervention pursued. Efficacy is successful control of PPH within 6 hours without additional surgery, confirmed by absence of active vaginal bleeding, contracted fundus and stable maternal condition.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Efficacy of intrauterine condom catheter balloon tamponade in control of primary postpartum hemorrhage
Tidsram: Within 6 hours of intervention and assessed for 30 minutes after deflation

Efficacy is defined as successful control of primary PPH within 6 hours of balloon insertion without need for additional surgical intervention. Success confirmed by absence of active vaginal bleeding, contracted uterine fundus on abdominal palpation and stable maternal vital signs and general condition. Failure defined as persistent bleeding or rising fundus requiring surgical intervention.

Within 6 hours of intervention and assessed for 30 minutes after deflation

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 oktober 2026

Primärt slutförande (Beräknad)

1 april 2027

Avslutad studie (Beräknad)

1 augusti 2027

Studieregistreringsdatum

Först inskickad

22 september 2026

Först inskickad som uppfyllde QC-kriterierna

22 september 2026

Första postat (Faktisk)

28 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data will not be shared due to institutional ethical restrictions and confidentiality of this academic dissertation project at Aziz Fatimah Hospital Faisalabad.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera